- Home
- HOTH vs EVAX Comparison
HOTH vs EVAX Comparison
Compare HOTH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- EVAX
- Stock Information
- Founded
- HOTH 2017
- EVAX 2008
- Country
- HOTH United States
- EVAX Denmark
- Employees
- HOTH N/A
- EVAX N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOTH Health Care
- EVAX Health Care
- Exchange
- HOTH Nasdaq
- EVAX Nasdaq
- Market Cap
- HOTH 15.6M
- EVAX 17.8M
- IPO Year
- HOTH 2019
- EVAX 2021
- Fundamental
- Price
- HOTH $1.60
- EVAX $2.94
- Analyst Decision
- HOTH Strong Buy
- EVAX Strong Buy
- Analyst Count
- HOTH 3
- EVAX 2
- Target Price
- HOTH $4.00
- EVAX $10.00
- AVG Volume (30 Days)
- HOTH 1.8M
- EVAX 89.3K
- Earning Date
- HOTH 11-11-2025
- EVAX 10-30-2025
- Dividend Yield
- HOTH N/A
- EVAX N/A
- EPS Growth
- HOTH N/A
- EVAX N/A
- EPS
- HOTH N/A
- EVAX N/A
- Revenue
- HOTH N/A
- EVAX $3,176,000.00
- Revenue This Year
- HOTH N/A
- EVAX N/A
- Revenue Next Year
- HOTH N/A
- EVAX N/A
- P/E Ratio
- HOTH N/A
- EVAX N/A
- Revenue Growth
- HOTH N/A
- EVAX 1042.45
- 52 Week Low
- HOTH $0.65
- EVAX $1.20
- 52 Week High
- HOTH $3.80
- EVAX $17.20
- Technical
- Relative Strength Index (RSI)
- HOTH 71.15
- EVAX 52.59
- Support Level
- HOTH $1.40
- EVAX $2.71
- Resistance Level
- HOTH $1.80
- EVAX $3.04
- Average True Range (ATR)
- HOTH 0.11
- EVAX 0.19
- MACD
- HOTH 0.04
- EVAX -0.02
- Stochastic Oscillator
- HOTH 68.75
- EVAX 57.53
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.